Carregant...
PD-1/PD-L1 inhibitors
Tumors may adopt normal physiologic checkpoints for immunomodulation leading to an imbalance between tumor growth and host surveillance. Antibodies targeting the PD-1/PD-L1 checkpoint have shown dynamic and durable tumor regressions, suggesting a rebalancing of the host-tumor interaction. Nivolumab...
Guardat en:
| Publicat a: | Curr Opin Pharmacol |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2015
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4516625/ https://ncbi.nlm.nih.gov/pubmed/26047524 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.coph.2015.05.011 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|